


Medicines & Healthcare products **Regulatory Agency**


Novel Primary Reference Materials to Support Standardisation in Liquid Biopsy



Needs for the harmonisation of measurement of genomic testing¹

- Primary reference materials
- . Primary reference measurement procedures
- . Framework for determining the measurement uncertainty in quantitative genomic data

¹https://www.genomemet.org/




Collaborative study design and preliminary results. (Left) Representative protocol of the collaborative study. Each **Dilution study results.** Representative data of serial dilutions. Candidate material **Material Production**. A target cell line was modified by introduction of selected EGFR variants. Each participant received three vials of the same material to be tested according to their established pipeline. (Middle) Four was diluted at different ratio with a similar EGFR wild-type material. Each EGFR single clone was validated orthogonally by a Sanger sequencing, NGS sequencing, digital PCR and Mass Array. The final formulation was empirically determined to contain nucleosomal DNA in human different methods were included: Bio-Rad droplet digital PCR, Qiagen digital PCR, Illumina NGS and Thermo Fisher variant was assesses independently by Bio-Rad digital PCR. Four ratios were NGS. (Right) Representative median Allele frequency (AF %) values obtained for each of the EGFR variants. Floating tested: Neat, 1:1. 1:5 and 1:10. Each data point represents the mean of 3 wells plasma matrix. Material was lyophilised, stored at -20°C and subject to periodical stability testing. boxes represent minimum and maximum values. Median values are identified by thick line. (Standard deviation is indicated by whiskers). Dotted lines represents calculated linear regression with CI 90%.

6. CONCLUSIONS

Here we describe the workflow for the generation of WHO Primary reference materials for harmonisation of measurement of genomic testing in oncology diagnostics. The implementation of these type of materials will expedite the development of primary reference measurement procedures as well as secondary reference materials. Ultimately, the development of a strong framework for precise and robust measurements of genomic variants, will benefit cancer patients worldwide.

Leandro Lo Cascio, Noble Ossai, Malcom Hawkins

Medicines and Healthcare products Regulatory Agency, South Mimms, Hertfordshire EN6 3QG Science & Research Group, Research & Development Team, Diagnostics Division, Genomics leandro.lo-cascio@mhra.gov.uk



anillalive	genomic	

COSMIC ID	CDS Mutation
COSV51765161	c.2573T>G
COSV51765492	c.2369C>T
COSV51765119	c.2235_2249del



7. ACKNOWLEDGEMENTS

This research was conducted at the Medicines and Healthcare products Regulatory Agency Science Campus. We gratefully acknowledge the significant contributions of all collaborative study R participants, that supported this work. We want to thanks all the colleagues of the Markets, Manufacturing and Logistics (MML) group at MHRA that contributed to this project.

